Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Sponsor: BeiGene
A PHASE2 clinical study on HER2-negative Breast Cancer, this trial is completed. The trial is conducted by BeiGene and has accumulated 11 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BeiGene
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Nanjing, China , Shanghai, China and 4 more locations